Arrowstreet Capital
BIOA

Arrowstreet Capital’s BioAge Labs BIOA Stock Holding History

Arrowstreet Capital’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Sell
49,545
-38,336
-44% -$693K ﹤0.01% 1616
2026
Q1 		$1.54M Buy
+87,881
New +$1.69M ﹤0.01% 1456

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Arrowstreet Capital's BIOA Position: Q2 2026 in Review

Arrowstreet Capital reduced its BioAge Labs (BIOA) stake by 44% in Q2 2026, selling an estimated $693K and leaving 49,545 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1616.

Arrowstreet Capital first reported a position in BIOA in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.54M in Q1 2026. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Arrowstreet Capital held 49,545 shares of BioAge Labs worth $1.21M as of Q2 2026.
  • Arrowstreet Capital sold 38,336 BioAge Labs shares in Q2 2026, an estimated $693K.
  • BioAge Labs made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1616 holding.
  • Arrowstreet Capital first reported a position in BioAge Labs in Q1 2026 and has held it in 2 quarters since.
  • Arrowstreet Capital's BioAge Labs position peaked at $1.54M in Q1 2026.
  • 150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.